Empiric immunization versus serologic screening: Developing a cost-effective strategy for the use of hepatitis A immunization in travelers

Journal of Travel Medicine

Volumn 9, Issue 2, 2002, Pages 71-75

  Fishbain, Joel T ^a,b   Eckart, Robert E ^a   Harner, Kyle C ^a   Hospenthal, Duane R ^a  

^a TRIPLER ARMY MEDICAL CENTER   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS A ANTIBODY; HEPATITIS A VACCINE;

ADULT; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; EMPIRICISM; HEPATITIS A; HUMAN; IMMUNIZATION; JAUNDICE; MAJOR CLINICAL STUDY; PREDICTION; PREVALENCE; RISK FACTOR; SCREENING; SEROLOGY; STATISTICAL ANALYSIS; TRAVEL; UNITED STATES;

EID: 0036237194     PISSN: 11951982     EISSN: None     Source Type: Journal    
DOI: 10.2310/7060.2002.21957     Document Type: Article

References (17)

1. Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (AC1P)
2. Immunizations and travel
3. Prevalence of anti-hepatitis A antibodies in an urban middle class area of Argentina: Some associated factors
4. Distribution of antibody to hepatitis A antigen in urban adult populations
5. History and epidemiology of hepatitis A virus
6. Prevalence of hepatitis A antibodies in Swiss travelers
7. Preventing hepatitis A infections in travelers to endemic areas
8. Licensure of inactivated hepatitis A vaccine and recommendations for use among international travelers
9. Safety and effectiveness of the new inactivated hepatitis A virus vaccine
10. Epidemiology and prevention of hepatitis A in travelers
11. Hepatitis A shifting epidemiology in Poland and Eastern Europe
12. Hepatitis A shifting epidemiology in South-East Asia and China
13. Hepatitis A shifting epidemiology in Latin America
14. Hepatitis A shifting epidemiology in the Middle East and Africa
15. Cost-effectiveness analysis of hepatitis A vaccination strategies for adults
16. Cost-effective analysis of hepatitis A prevention in Ireland
17. Testing for antibody to hepatitis A to decrease the cost of hepatitis A prophylaxis with immune globulin or hepatitis A vaccines